Freestone Grove Partners LP Makes New Investment in Veracyte, Inc. $VCYT

Posted by George Bondi on Aug 28th, 2026

Freestone Grove Partners LP purchased a new stake in Veracyte, Inc. (NASDAQ:VCYT – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 299,911 shares of the biotechnology company’s stock, valued at approximately $17,614,000. Freestone Grove Partners LP owned 0.37% of Veracyte at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in VCYT. Bank of America Corp DE grew its position in Veracyte by 14.7% during the first quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock worth $46,669,000 after buying an additional 185,929 shares in the last quarter. Summit Creek Advisors LLC purchased a new stake in shares of Veracyte in the 2nd quarter valued at about $6,986,000. William Blair Investment Management LLC raised its holdings in shares of Veracyte by 16.6% in the 4th quarter. William Blair Investment Management LLC now owns 790,425 shares of the biotechnology company’s stock valued at $33,277,000 after acquiring an additional 112,516 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of Veracyte during the 2nd quarter valued at about $5,913,000. Finally, California State Teachers Retirement System boosted its position in shares of Veracyte by 24.4% during the 1st quarter. California State Teachers Retirement System now owns 93,029 shares of the biotechnology company’s stock valued at $2,996,000 after acquiring an additional 18,261 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently weighed in on VCYT shares. Zacks Research upgraded shares of Veracyte from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 11th. Stephens dropped their target price on shares of Veracyte from $68.00 to $55.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. UBS Group boosted their price target on shares of Veracyte from $48.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Canaccord Genuity Group lowered their price objective on shares of Veracyte from $60.00 to $50.00 and set a “hold” rating on the stock in a research report on Monday, August 3rd. Finally, Wolfe Research assumed coverage on shares of Veracyte in a report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.33.

Read Our Latest Research Report on Veracyte

Veracyte Price Performance

Shares of VCYT opened at $45.25 on Friday. The firm has a market cap of $3.64 billion, a P/E ratio of 32.09 and a beta of 1.95. The stock has a 50 day simple moving average of $52.13 and a two-hundred day simple moving average of $42.85. Veracyte, Inc. has a 1 year low of $28.55 and a 1 year high of $60.91.

Veracyte (NASDAQ:VCYT – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $150.32 million for the quarter, compared to analysts’ expectations of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. The business’s quarterly revenue was up 15.5% on a year-over-year basis. During the same period last year, the business earned $0.44 earnings per share. On average, equities analysts anticipate that Veracyte, Inc. will post 1.32 earnings per share for the current year.

Insider Buying and Selling

In other Veracyte news, CEO Marc Stapley sold 138,051 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the completion of the sale, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at $22,077,559.28. The trade was a 23.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Karin Eastham sold 3,729 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.89, for a total transaction of $197,226.81. Following the sale, the director owned 15,097 shares of the company’s stock, valued at approximately $798,480.33. The trade was a 19.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,492 shares of company stock worth $8,151,197 in the last ninety days. 1.60% of the stock is currently owned by insiders.

Veracyte Profile

(Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.